New Gene Mutation Associated with Fanconi Anemia
|
By LabMedica International staff writers Posted on 25 Jul 2017 |

Image: The enzyme E3 ubiquitin ligase (RFWD3) helps target other proteins on single-stranded DNA for degradation. B: Cells lacking RFWD3 show DNA repair defects (Photo courtesy of Julius-Maximilians-Universität).
Fanconi anemia is a rare genetic disease characterized by bone marrow failure heralded by low platelet counts and unusually large red blood cells. Mutations in over 20 genes have been identified as causative for Fanconi anemia, which encode proteins commonly involved in DNA repair mechanisms.
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Latest Molecular Diagnostics News
- New NGS Panel Detects AML Fusions at MRD-Level Sensitivity
- Spinal Fluid Liquid Biopsy May Help Clarify Uncertain Brain Tumor Findings
- Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment
- RNA Sequencing Assay Gains EU Certification for Solid Tumor Profiling
- Whole-Genome MRD Test Detects Traces of Cancer During and After Treatment
- Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer
- Updated Framework Guides Assessment of Actionable Cancer Biomarkers
- Six-Gene Score Improves Prognosis Prediction in Acute Myeloid Leukemia
- Long-Read Sequencing Reveals Cancer-Driving Changes Missed by Conventional Testing
- Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
- Donor-Derived DNA Testing May Reduce Biopsies in Kidney Transplant Monitoring
- AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
- New Variant Tracking Option Expands Molecular Residual Disease Monitoring
- Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
- Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis
- GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreHematology
view channel
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read moreImmunology
view channel
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
COVID-19 and Flu Combo Test Launches With FDA Clearance
Overlapping symptoms of COVID-19 and influenza can create diagnostic uncertainty, particularly in urgent and point-of-care settings. Rapid differentiation from a single specimen can streamline triage and... Read moreMicrobiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
For many patients, cancer treatment does not eliminate the risk of recurrence, which may occur months or years later and become harder to treat after spreading. Recurrence is often detected only after... Read more







